Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Persistence of Solifenacin Treatment in Overactive Bladder Patients in Real Life Practice: A 12-month, Prospective, Multicenter, Open-label, Observational Study

NCT00985387 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT00985387
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00985387 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Persistence of Solifenacin Treatment in Overactive Bladder Patients in Real Life Practice: A 12-month, Prospective, Multicenter, Open-label, Observational Study
Lead sponsor
Astellas Pharma Inc
Phase
Observational
Overall status
Completed
Start date
August 31, 2009
Completion date
August 31, 2011
Enrollment
1,215 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

overactive bladder, urinary bladder, overactive